Welcome to PsychU!

Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Virtual Event – The Evolving Psychopharmacology Of Major Depressive Disorder

In this presentation, the objectives are to:

  • Provide a brief overview of depression prevalence and current standard treatments
  • Review the monoamine hypothesis of depression
  • Discuss alternative hypotheses of depression
  • Highlight potential new therapeutic intervention targets

Featuring

Philip G.-Janicak

Philip G. Janicak, MD

Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association

More
Dr. Janicak is an Adjunct Professor and Consultant to the Therapeutic Neuromodulation Program in the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine and a Distinguished Life Fellow in the American Psychiatric Association. He completed his medical training and psychiatric residency at Loyola University of Chicago in 1976. In 1978, he became a research psychiatrist at the Illinois State Psychiatric Institute. He was a Professor of Psychiatry and Pharmacology, the Medical Director of the Psychiatric Clinical Research Center, and the Associate Program Director for the NIH General Clinical Research Center at the University of Illinois Medical Center from 1994-2004. He then became a Professor of Psychiatry at Rush University and was the Director of the Rush Psychiatric Clinical Research and Transcranial Magnetic Stimulation Centers from 2004-2014. He developed and directed the TMS Center at Linden Oaks Medical Group from 2014-2017. Dr. Janicak’s primary research interests are in the assessment and treatment of mood and psychotic disorders. In this context, he has conducted over 60 clinical trials. He has been a NIH grant awardee as both a principal and co-investigator. He has authored, co-authored or edited over 500 publications in the psychiatric literature and is first author of the Principles and Practice of Psychopharmacotherapy. Dr. Janicak was the editor of the Psychopharm Review from 2004-2014 and presently serves on the Editorial Board of Current Psychiatry. He has also been a reviewer for several journals, including: The American Journal of Psychiatry, Biological Psychiatry, JAMA Psychiatry, Journal of the American Medical Association, Journal of ECT, Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Psychiatric Annals, Psychiatry Research and Schizophrenia Research. Dr. Janicak was first listed in the Best Doctors of America since 1996 and Who’s Who in America in 2001. Dr. Janicak was named Psychiatrist of the Year by NAMI Illinois for 2003. In 2009, he received the John M. Davis Researcher of the Year Award from NAMI of Greater Chicago. In 2017, he was a recipient of the Who’s Who Albert Nelson Marquis Lifetime Achievement Award. In 2018, he was the recipient of the Illinois Psychiatric Society Educator of the Year Award. He has participated as a principal lecturer in over 500 courses, seminars, symposia and related professional presentations.
Rachel-Self

Rachel Self, PhD, MS (OPDC)

Medical Science Director, Neuroscience Field Medical Affairs

More
Rachel Self, PhD, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs, neuroscientist, & wellness advocate.

Registration

Related Resources

Join today for instant access to all PsychU content, events, and more!

Membership is free!

Join PsychU Today to receive a wide array of tools and benefits

  • Join our multidisciplinary community that is improving mental health care… together
  • Quickly learn more about the topics you're interested in
  • Access an award-winning library of on-demand mental health resources
  • Gain key insights from industry expert & thought leaders